VOMITING is the #5 most commonly reported adverse reaction for CETUXIMAB, manufactured by ImClone LLC. There are 1,372 FDA adverse event reports linking CETUXIMAB to VOMITING. This represents approximately 2.7% of all 51,547 adverse event reports for this drug.
Patients taking CETUXIMAB who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
VOMITING1,372 of 51,547 reports
VOMITING is a less commonly reported adverse event for CETUXIMAB, but still significant enough to appear in the safety profile.
Other Side Effects of CETUXIMAB
In addition to vomiting, the following adverse reactions have been reported for CETUXIMAB:
VOMITING has been reported as an adverse event in 1,372 FDA reports for CETUXIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is VOMITING with CETUXIMAB?
VOMITING accounts for approximately 2.7% of all adverse event reports for CETUXIMAB, making it a notable side effect.
What should I do if I experience VOMITING while taking CETUXIMAB?
If you experience vomiting while taking CETUXIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.